Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2013 - 2026)

Amphastar Pharmaceuticals has reported Accumulated Expenses for 14 years, with the latest figure at $222.4 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 78.42% year-over-year to $222.4 million in Q2 2026; TTM through Jun 2026 was $222.4 million, a 78.42% increase from a year earlier, with the FY2025 full-year figure at $115.8 million, down 8.52% from the prior year.
• Accumulated Expenses was $222.4 million for Q2 2026 at Amphastar Pharmaceuticals, up from $117.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $222.4 million in Q2 2026, with the low at $63.7 million in Q4 2022.
• Average Accumulated Expenses over 5 years is $115.6 million, with a median of $116.5 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses soared 198.38% in 2023, then tumbled 49.96% in 2024.
• Over 5 years, Accumulated Expenses stood at $63.7 million in 2022, then gained by 6.57% to $67.9 million in 2023, then jumped by 86.29% to $126.5 million in 2024, then retreated by 8.52% to $115.8 million in 2025, then jumped by 92.17% to $222.4 million in 2026.
• The last three Accumulated Expenses figures came in at $222.4 million (Q2 2026), $117.2 million (Q1 2026), and $115.8 million (Q4 2025), per Business Quant data.